Drug Resistance in Cancer: An Overview
Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/6/3/1769 |
| _version_ | 1797711749684658176 |
|---|---|
| author | Genevieve Housman Shannon Byler Sarah Heerboth Karolina Lapinska Mckenna Longacre Nicole Snyder Sibaji Sarkar |
| author_facet | Genevieve Housman Shannon Byler Sarah Heerboth Karolina Lapinska Mckenna Longacre Nicole Snyder Sibaji Sarkar |
| author_sort | Genevieve Housman |
| collection | DOAJ |
| description | Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance. It also describes the epigenetic modifications that can induce drug resistance and considers how such epigenetic factors may contribute to the development of cancer progenitor cells, which are not killed by conventional cancer therapies. Lastly, this review concludes with a discussion on the best treatment options for existing drug resistant cancers, ways to prevent the formation of drug resistant cancers and cancer progenitor cells, and future directions of study. |
| first_indexed | 2024-03-12T07:11:43Z |
| format | Article |
| id | doaj.art-efd0a3195c894dabb69ef79ceca4264f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T07:11:43Z |
| publishDate | 2014-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-efd0a3195c894dabb69ef79ceca4264f2023-09-02T23:05:22ZengMDPI AGCancers2072-66942014-09-01631769179210.3390/cancers6031769cancers6031769Drug Resistance in Cancer: An OverviewGenevieve Housman0Shannon Byler1Sarah Heerboth2Karolina Lapinska3Mckenna Longacre4Nicole Snyder5Sibaji Sarkar6School of Human Evolution and Social Change, Arizona State University, Tempe, AZ 85287, USACancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USACancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USACancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USAHarvard Medical School, Boston, MA 02115, USACancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USACancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USACancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance. It also describes the epigenetic modifications that can induce drug resistance and considers how such epigenetic factors may contribute to the development of cancer progenitor cells, which are not killed by conventional cancer therapies. Lastly, this review concludes with a discussion on the best treatment options for existing drug resistant cancers, ways to prevent the formation of drug resistant cancers and cancer progenitor cells, and future directions of study.http://www.mdpi.com/2072-6694/6/3/1769cancerdrug resistanceepigeneticsmethylationcancer progenitor cellscombination therapyreview |
| spellingShingle | Genevieve Housman Shannon Byler Sarah Heerboth Karolina Lapinska Mckenna Longacre Nicole Snyder Sibaji Sarkar Drug Resistance in Cancer: An Overview Cancers cancer drug resistance epigenetics methylation cancer progenitor cells combination therapy review |
| title | Drug Resistance in Cancer: An Overview |
| title_full | Drug Resistance in Cancer: An Overview |
| title_fullStr | Drug Resistance in Cancer: An Overview |
| title_full_unstemmed | Drug Resistance in Cancer: An Overview |
| title_short | Drug Resistance in Cancer: An Overview |
| title_sort | drug resistance in cancer an overview |
| topic | cancer drug resistance epigenetics methylation cancer progenitor cells combination therapy review |
| url | http://www.mdpi.com/2072-6694/6/3/1769 |
| work_keys_str_mv | AT genevievehousman drugresistanceincanceranoverview AT shannonbyler drugresistanceincanceranoverview AT sarahheerboth drugresistanceincanceranoverview AT karolinalapinska drugresistanceincanceranoverview AT mckennalongacre drugresistanceincanceranoverview AT nicolesnyder drugresistanceincanceranoverview AT sibajisarkar drugresistanceincanceranoverview |